Pharnext company logo
Analyst Briefing Submitted
pharnext.com

Founded Year

2007

Stage

PIPE | IPO

Total Raised

$20.01M

Market Cap

0.00B

About Pharnext

Pharnext specializes in the development of drugs based on PleotherapyTM for the treatment of severe, rare and common neurological diseases (including Alzheimer, Charcot-Marie Tooth disease, Parkinson's and amyotrophic lateral sclerosis). The company keeps creating new treatments by combining, at very low doses, molecules that are already tested for other diseases.

Pharnext Headquarter Location

11-13 rue René Jacques

Issy-les-Moulineaux, 92130,

France

+33 (0)1 41 09 22 30

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Pharnext's Products & Differentiation

See Pharnext's products and how their products differentiate from alternatives and competitors

  • PXT3003

    CMT1A treatment under development

Expert Collections containing Pharnext

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Pharnext is included in 2 Expert Collections, including Biopharma Tech.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

D

Dental Health

957 items

Companies delivering dental care products and services. Excludes practice networks.

Pharnext Patents

Pharnext has filed 66 patents.

The 3 most popular patent topics include:

  • Neurological disorders
  • Analgesics
  • Rare diseases
patents chart

Application Date

Grant Date

Title

Related Topics

Status

10/29/2010

4/5/2022

Clusters of differentiation, Transcription factors, G protein coupled receptors, Human proteins, Fluoroarenes

Grant

Application Date

10/29/2010

Grant Date

4/5/2022

Title

Related Topics

Clusters of differentiation, Transcription factors, G protein coupled receptors, Human proteins, Fluoroarenes

Status

Grant

Latest Pharnext News

Beyond Biotech podcast 1: Forbion, OMass, PharNext

Jun 17, 2022

It’s the first official Beyond Biotech podcast! And this week, we have three interviews. We talked with Ros Deegan, CEO of OMass; David Solomon, CEO of PharNext; and two people from Forbion, Sander Slootweg, managing partner, and Dirk Mertens, general partner. Forbion European life sciences venture capital firm Forbion, has announced the first €470M ($500M) close of its Forbion Growth Opportunities Fund II. The fund will focus on investing in late-stage European life sciences companies. The new fund has attracted several new institutional investors, including pension funds PME and PMT, the Ewing Marion Kauffman Foundation and Reggeborgh, who join returning investors Pantheon, Wealth Management Partners and Eli Lilly and Company. The second fund will invest in mostly European, later-stage biopharma companies, developing novel therapies for areas of high medical need. Content continues below OMass The UK firm OMass Therapeutics recently unveiled a €90 million Series B financing to bankroll the development of small molecules against so-called ‘undruggable’ targets, including one that sank Quench Bio last year. In 2020, Quench Bio captured the imagination of investors with the US firm’s ambition to develop a new class of anti-inflammatory drugs. The startup aimed to block the protein gasdermin D, which is linked to a host of conditions including rheumatoid arthritis, multiple sclerosis, and nonalcoholic steatohepatitis (NASH). Following Quench’s experience, OMass Therapeutics’ Series B round will finance its own shot at gasdermin D. PharNext Pharnext SA , an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high unmet medical need, has completed the enrollment of 387 patients in its pivotal phase 3 clinical study of PXT3003, the PREMIER trial, in Charcot-Marie-Tooth disease type 1A (‘CMT1A’). Explore Related Topics:

Pharnext Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Pharnext Rank

  • When was Pharnext founded?

    Pharnext was founded in 2007.

  • Where is Pharnext's headquarters?

    Pharnext's headquarters is located at 11-13 rue René Jacques, Issy-les-Moulineaux.

  • What is Pharnext's latest funding round?

    Pharnext's latest funding round is PIPE.

  • How much did Pharnext raise?

    Pharnext raised a total of $20.01M.

  • Who are the investors of Pharnext?

    Investors of Pharnext include CB Lux, Truffle Capital, Parinvest, La Financiere Gaspard, Claude Darmon and 6 more.

  • What products does Pharnext offer?

    Pharnext's products include PXT3003.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.